A Ten-N6-Methyladenosine (m6A)-Modified Gene Signature Based on a Risk Score System Predicts Patient Prognosis in Rectum Adenocarcinoma

Abstract

ObjectivesThe study aims to analyze the expression of N6-methyladenosine (m6A)-modified genes in rectum adenocarcinoma (READ) and identify reliable prognostic biomarkers to predict the prognosis of READ.Materials and MethodsRNA sequence data of READ and corresponding clinical survival data were obtained from The Cancer Genome Atlas (TCGA) database. N6-methyladenosine (m6A)-modified genes in READ were downloaded from the “m6Avar” database. Differentially expressed m6A-modified genes in READ stratified by different clinicopathological characteristics were identified using the “limma” package in R. Protein-protein interaction (PPI) network and co-expression analysis of differentially expressed genes (DEGs) were performed using “STRING” and Cytoscape, respectively. Principal component analysis (PCA) was done using R. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were used to functionally annotate the differentially expressed genes in different subgroups. Univariate Cox regression analyses were conducted to identify the powerful independent prognostic factors in READ associated with overall survival (OS). A robust likelihood-based survival model was built using the “rbsurv” package to screen for survival-associated signature genes. The Support Vector Machine (SVM) was used to predict the prognosis of READ through the risk score of survival-associated signature genes. Correlation analysis were carried out using GraphPad prism 8.ResultsWe screened 974 differentially expressed m6A-modified genes among four types of READ samples. Two READ subgroups (group 1 and group 2) were identified by K means clustering according to the expression of DEGs. The two subgroups were significantly different in overall survival and pathological stages. Next, 118 differentially expressed genes between the two subgroups were screened and the expression of 112 genes was found to be related to the prognosis of READ. Next, a panel of 10 survival-associated signature genes including adamtsl1, csmd2, fam13c, fam184a, klhl4, olfml2b, pdzd4, sec14l5, setbp1, tmem132b was constructed. The signature performed very well for prognosis prediction, time-dependent receiver-operating characteristic (ROC) analysis displaying an area under the curve (AUC) of 0.863, 0.8721, and 0.8752 for 3-year survival rate, prognostic status, and pathological stage prediction, respectively. Correlation analysis showed that the expression levels of the 10 m6A-modified genes were positively correlated with that of m6A demethylase FTO and ALKBH5.ConclusionThis study identified potential m6A-modified genes that may be involved in the pathophysiology of READ and constructed a novel gene expression panel for READ risk stratification and prognosis prediction.

Identification of an m6A Regulators-Mediated Prognosis Signature For Survival Prediction and Its Relevance to Immune Infiltration in Melanoma

“…Other m6A-related prognostic signatures also achieved good performance in predicting the prognosis of multiple malignant tumors, including hepatocellular carcinoma, rectum adenocarcinoma, gastric cancer ( Guan et al, 2020 ; Huang et al, 2020 ; Shen et al, 2020 ). Compared with other clinical factors (gender, age, TNM stage), the risk signature showed a beneficial supplement to prognostic factors for melanoma.…”

Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment

“…DSEL can also function as a validated biomarker to predict OS in bladder cancer ( 30 ). SEC14L5 was thought to be closely associated with rectum adenocarcinoma ( 31 ), lung cancer ( 8 ) and others. This study revealed a statistically significant relationship between the expression of SEC14L5 and the progression of LUAD.…”

Analysis of Prognostic and Therapeutic Values of Drug Resistance-Related Genes in the Lung Cancer Microenvironment

“…DSEL can also function as a validated biomarker to predict overall survival in bladder cancer [30]. SEC14L5 was thought to be closely associated with rectum adenocarcinoma [31], lung cancer [7] and others. This study revealed a statistically signi cant relationship between the expression of SEC14L5 and the progression of LUAD.…”